PHOENIX, Feb. 8, 2021 /PRNewswire/ — (OTC-CELZ) Inventive Medical Know-how Holdings Inc. introduced in the present day recruitment of Dr. Caigan Du, Affiliate Professor on the College of British Columbia to the Firm’s Scientific Advisory Board.
Dr. Du is a high researcher within the space of molecular and immunological understanding of kidney failure and transplant rejection. Dr. Du is funded by quite a few nationwide and worldwide organizations together with the Kidney Basis and the Canadian Institutes of Well being Analysis.
“I’m honored to work with Inventive Medical Know-how Holdings on this fascinating area of leveraging reprogrammed immune cells for regenerating injured kidneys.” Stated Dr. Du. “Thus far individuals take into consideration regenerative medication and immunology as separate fields. It is vitally thrilling to contemplate the chance that immune cells can act as a catalyst for regenerative processes: that is the idea of the ImmCelz® product.”
ImmCelz® is a customized cell remedy generated by incubation of affected person cells with allogeneic JadiCell stem cells beneath proprietary situations. The JadiCell possess potent skill to reprogram the immune system, as exemplified partly by their skill to considerably prolong survival of COVID sufferers in an FDA double blind, placebo managed, medical trial1. ImmCelz® has been demonstrated efficient in animal fashions of rheumatoid arthritis2, liver failure3, stroke4, sort 1 diabetes5 and kidney failure6. Scientific research counsel ImmCelz® capabilities by means of secretion of a basically vital molecule known as Hepatocyte Development Issue7, in addition to stimulation of T regulatory cells, a kind of immune system cell that suppresses pathological immunity8.
“As a clinical-stage biotechnology firm, having already commercialized different stem cell merchandise, we perceive the important thing to any success relies on the power to draw scientific key opinion leaders.” Stated Timothy Warbington, President and CEO of Inventive Medical Know-how Holdings. “Dr. Du is a visionary and pioneer in understanding of kidney ailments and we wholeheartedly look ahead to him becoming a member of our scientific advisory board.”
The Advisory Board of Inventive Medical Know-how Holdings consists of internationally famend neurologist Santosh Kesari MD, Ph.D, the previous head of cardiology at Cedar Sinai Medical Heart Timothy Henry, MD and our Director Dr. Amit Patel, inventor of the JadiCell and the primary doctor to have implanted stem cells into the human coronary heart.
About Inventive Medical Know-how Holdings
Inventive Medical Know-how Holdings, Inc. is a industrial stage biotechnology firm specializing in regenerative medication/stem cell expertise within the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC beneath the ticker image CELZ. For additional details about the corporate, please go to www.creativemedicaltechnology.com.
Ahead Wanting Statements
OTC Markets has not reviewed and doesn’t settle for duty for the adequacy or accuracy of this launch. This information launch might comprise forward-looking statements together with however not restricted to feedback concerning the timing and content material of upcoming medical trials and laboratory outcomes, advertising and marketing efforts, funding, and so forth. Ahead-looking statements tackle future occasions and situations and, due to this fact, contain inherent dangers and uncertainties. Precise outcomes might differ materially from these at the moment anticipated in such statements. See the periodic and different studies filed by Inventive Medical Know-how Holdings, Inc. with the Securities and Alternate Fee and accessible on the Fee’s web site at www.sec.gov.
1 Umbilical cord mesenchymal stem cells for COVID–19 acute respiratory distress syndrome: A double–blind, phase 1/2a, randomized controlled trial – Lanzoni – – STEM CELLS Translational Medicine – Wiley Online Library
2 Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace
3 Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model | Nasdaq
4 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
5 Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes (prnewswire.com)
6 Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz® Regenerative Immunotherapy (prnewswire.com)
7 Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity (apnews.com)
8 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
SOURCE Inventive Medical Know-how Holdings, Inc.